[go: up one dir, main page]

ATE388162T1 - Verfahren zur beseitigung von viren - Google Patents

Verfahren zur beseitigung von viren

Info

Publication number
ATE388162T1
ATE388162T1 AT98953439T AT98953439T ATE388162T1 AT E388162 T1 ATE388162 T1 AT E388162T1 AT 98953439 T AT98953439 T AT 98953439T AT 98953439 T AT98953439 T AT 98953439T AT E388162 T1 ATE388162 T1 AT E388162T1
Authority
AT
Austria
Prior art keywords
methods
immunoglobulin
excipient
viruses
elimination
Prior art date
Application number
AT98953439T
Other languages
English (en)
Inventor
Holten Robert Van
George E Oulundsen
Original Assignee
Ortho Clinical Diagnostics Inc
Millipore Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Clinical Diagnostics Inc, Millipore Corp filed Critical Ortho Clinical Diagnostics Inc
Application granted granted Critical
Publication of ATE388162T1 publication Critical patent/ATE388162T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/022—Filtration
    • A61L2103/05—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/88—Manufacture, treatment, or detection of nanostructure with arrangement, process, or apparatus for testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation By Low-Temperature Treatments (AREA)
  • Glass Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Piles And Underground Anchors (AREA)
AT98953439T 1997-10-14 1998-10-14 Verfahren zur beseitigung von viren ATE388162T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/950,157 US6096872A (en) 1997-10-14 1997-10-14 Viral clearance process

Publications (1)

Publication Number Publication Date
ATE388162T1 true ATE388162T1 (de) 2008-03-15

Family

ID=25490036

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98953439T ATE388162T1 (de) 1997-10-14 1998-10-14 Verfahren zur beseitigung von viren

Country Status (12)

Country Link
US (1) US6096872A (de)
EP (1) EP1030862B1 (de)
JP (1) JP4255210B2 (de)
KR (1) KR100547077B1 (de)
CN (2) CN1163503C (de)
AT (1) ATE388162T1 (de)
AU (1) AU744845B2 (de)
CA (1) CA2306181C (de)
DE (1) DE69839218T2 (de)
ES (1) ES2302361T3 (de)
NO (1) NO326392B1 (de)
WO (1) WO1999019343A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5080713B2 (ja) * 1999-12-20 2012-11-21 田辺三菱製薬株式会社 多孔性膜処理によるウイルスの除去された血漿蛋白組成物の製造方法、ウイルスの除去された血漿蛋白組成物およびウイルス除去方法
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
US6365395B1 (en) * 2000-11-03 2002-04-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
AU784808B2 (en) * 2001-04-02 2006-06-29 Kedrion Melville Inc. Prion and viral clearance process
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
KR100451308B1 (ko) * 2001-12-28 2004-10-06 선바이오(주) 단백질 의약품 정제 방법에서의 바이러스 제거 방법
WO2003066669A2 (en) * 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
DE10211632A1 (de) * 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
US7201901B2 (en) 2002-05-23 2007-04-10 Ortho-Clinical Diagnostics, Inc. Capture, concentration and quantitation of abnormal prion protein from biological fluids using depth filtration
AU2003239959A1 (en) * 2002-06-14 2003-12-31 Centocor, Inc. Use of a clathrate modifier to promote passage of proteins during nanofiltration
WO2004024752A1 (ja) * 2002-09-11 2004-03-25 Chugai Seiyaku Kabushiki Kaisha タンパク質精製方法
US20040116676A1 (en) * 2002-09-30 2004-06-17 Hotta Joann Methods for removal of contaminants from blood product solutions
EP3178492A1 (de) 2003-04-04 2017-06-14 Genentech, Inc. Hochkonzentrierte antikörper- und proteinformulierungen
ES2290553T3 (es) * 2003-05-19 2008-02-16 Millipore Corporation Procedimiento para prefiltrar una solucion de proteinas.
AU2005229674B2 (en) * 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
US20060270015A1 (en) * 2005-05-26 2006-11-30 Dan Pawlak Thrombin purification
JP5547477B2 (ja) * 2006-06-26 2014-07-16 オムリクス・バイオフアーマシユーチカルズ・インコーポレーテツド ナノ濾過によるウイルス除去
CN101489655A (zh) * 2006-07-14 2009-07-22 威斯康星旧生研究基金会 捕获病毒用吸附膜
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
EP2271382B1 (de) * 2008-04-15 2013-03-13 Grifols Therapeutics Inc. Zweistufige Ultrafiltrierung/Diafiltrierung
CN102414221A (zh) * 2009-03-06 2012-04-11 健泰科生物技术公司 抗体配制剂
WO2010132288A1 (en) * 2009-05-11 2010-11-18 Millipore Corporation Method for scaling mixing operations
WO2012082933A1 (en) 2010-12-15 2012-06-21 Baxter International, Inc. Eluate collection using conductivity gradient
KR20120098202A (ko) * 2011-02-28 2012-09-05 (주)차바이오앤디오스텍 자하거 추출물 및 자하거 추출물 제조 방법
PL2697369T3 (pl) * 2011-03-25 2018-12-31 F.Hoffmann-La Roche Ag Nowe sposoby oczyszczania białek
MX359235B (es) 2011-09-01 2018-09-20 Chugai Pharmaceutical Co Ltd Metodo para preparar una composicion que comprende anticuerpos altamente concentrados por ultrafiltracion.
CN102599332B (zh) * 2012-03-09 2014-07-30 上海杰隆生物制品股份有限公司 一种利用禽血生产低灰分禽血浆蛋白粉的方法
US9867852B2 (en) * 2012-12-20 2018-01-16 Omrix Biopharmaceuticals Ltd. Viral inactivated biological mixture
WO2015140751A1 (en) * 2014-03-21 2015-09-24 Boreal Invest Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
BR112016025854B1 (pt) * 2014-05-13 2022-03-03 Amgen Inc Sistema de controle de processo; método de controle de processo para uso com uma ou mais unidades de processamento e processo para purificar uma proteína
CN107073397A (zh) 2014-05-21 2017-08-18 非链实验室 用于缓冲溶液交换的系统和方法
EP3909609A1 (de) 2016-05-27 2021-11-17 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von refraktärer generalisierter myasthenia gravis
EP3498828B1 (de) * 2016-08-09 2021-11-03 Asahi Kasei Medical Co., Ltd. Verfahren zur behandlung einer mit schweine-circoviren verunreinigten lösung
BR112020008182A2 (pt) 2017-10-26 2020-10-27 Alexion Pharmaceuticals, Inc. dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua)
US12312394B2 (en) 2018-06-28 2025-05-27 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5 antibodies
EP3636657A1 (de) * 2018-10-08 2020-04-15 Ablynx N.V. Chromatographiefreies antikörperreinigungsverfahren
CN116297915B (zh) * 2023-02-10 2023-12-01 中国食品药品检定研究院 聚山梨酯类辅料的分析鉴定方法
FR3157849A1 (fr) * 2023-12-27 2025-07-04 Technip Energies France Méthode d’installation d’un dispositif d’ancrage sur fond marin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3449314A (en) * 1966-06-03 1969-06-10 Ortho Pharma Corp Preparation of anti-rh globulin from human plasma
US3916026A (en) * 1968-09-19 1975-10-28 Biotest Serum Institut Gmbh Method for the preparation of gamma-globulin suitable for intravenous use
US4021540A (en) * 1975-07-28 1977-05-03 Ortho Diagnostics Inc. Preparation of a hepatitis B immune globulin and use thereof as a prophylactic material
DE2624373C2 (de) * 1976-05-31 1983-02-03 Arnold Dr. 8782 Karlstadt Seufert Verfahren zur Herstellung von steril filtriertem Kryopräzipilat mit einer Anreicherung des Faktors VIII
US4590002A (en) * 1984-12-10 1986-05-20 Ortho Diagnostic Systems, Inc. Methods for preparation of highly purified, gamma globulins free of hepatitis-B-virus infectivity
DE3641115A1 (de) * 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
US5115101A (en) * 1988-06-08 1992-05-19 Miles Inc. Removal of protein A from antibody preparations
FR2639645B1 (fr) * 1988-11-25 1992-05-29 Elf Aquitaine Solutions liquides concentrees de polysaccharides
DE4137996A1 (de) * 1991-11-19 1993-05-27 Behringwerke Ag Verfahren zur herstellung eines virussicheren thrombinkonzentrates
SE9500724D0 (sv) * 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
FR2724182B1 (fr) * 1994-09-02 1996-12-13 Pasteur Institut Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations
ES2332893T3 (es) * 1996-08-30 2010-02-15 Upfront Chromatography A/S Aislamiento de inmunoglobulinas.

Also Published As

Publication number Publication date
KR100547077B1 (ko) 2006-02-01
CA2306181A1 (en) 1999-04-22
JP2002500164A (ja) 2002-01-08
EP1030862A4 (de) 2002-10-23
US6096872A (en) 2000-08-01
CN1163503C (zh) 2004-08-25
ES2302361T3 (es) 2008-07-01
AU744845B2 (en) 2002-03-07
EP1030862B1 (de) 2008-03-05
CN1576281B (zh) 2012-08-08
DE69839218D1 (de) 2008-04-17
DE69839218T2 (de) 2009-03-19
WO1999019343A1 (en) 1999-04-22
CA2306181C (en) 2010-09-21
CN1279688A (zh) 2001-01-10
AU1081799A (en) 1999-05-03
NO20001949L (no) 2000-06-14
JP4255210B2 (ja) 2009-04-15
NO326392B1 (no) 2008-11-24
KR20010015753A (ko) 2001-02-26
NO20001949D0 (no) 2000-04-13
CN1576281A (zh) 2005-02-09
EP1030862A1 (de) 2000-08-30

Similar Documents

Publication Publication Date Title
ATE388162T1 (de) Verfahren zur beseitigung von viren
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
DE69632224D1 (de) Reduzierung von Gelation von Fettsäureacylierten Proteinen unter Nutzung von Zitratpuffer
CA2290485A1 (en) Method for the production of non-immunogenic proteins
ATE200679T1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
ATE123780T1 (de) Verfahren zur verwendung und herstellung von peptiden.
NO177188C (no) Fremgangsmåte for separering av humane eller animalske plasmaproteiner
ATE432948T1 (de) Verfahren zur beseitigung von viren und prionen aus immunglobulinzusammensetzungen
DE59003771D1 (de) Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte.
DE3773963D1 (de) Verfahren zur herstellung von reifem, menschlichem serum-albumin.
ATE154200T1 (de) Verfahren zur gewinnung von alpha-lactalbumin und beta-lactoglobulin aus einem molkeproteinprodukt
DE3768833D1 (de) Verfahren zur herstellung von hcmv-glykoproteinen, antikoerper dagegen und hcmv-vakzine und dazu zu verwendende rekombinante vektoren.
DK322188D0 (da) Fremgangsmaade til fremstilling af protein
DE59209512D1 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
ATE279441T1 (de) Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen
BR9709569B1 (pt) processo para ativação de proteìna desnaturada.
AT379510B (de) Verfahren zur herstellung einer faktor viii (ahf) -haeltigen praeparation
DE69434221D1 (de) Bindungs domänen von plasmodium vivax und plasmodium falciparum erythrozyten-bindenden proteinen
WO1996040766A3 (en) Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins
ATE166881T1 (de) Verfahren zur herstellung von faktor viii
ATE212360T1 (de) Polyethylenglycol-hirudin-konjugate, deren verfahren zur herstellung und verwendung für die heilung von thrombosen
ATE118982T1 (de) Verfahren zur herstellung von transparenten milchmolkeproteinen und milchmolkeproteinprodukte.
FI102383B1 (fi) Menetelmä ja plasmidi modifioidun PE40-domeenia sisältävän hybridiproteiinin valmistamiseksi
DE59310073D1 (de) Verfahren zur Inaktivierung von Viren in Präparationen von Proteinen
DE3882154D1 (de) Verfahren zur herstellung des pres 1/s2/s-hepatitis-b-antigens aus hefe.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties